Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda gains non-exclusive access to Alnylam’s RNAi therapeutics platform in oncology and metabolic disease for $150 million upfront.

You may also be interested in...



Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.

Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.

Alnylam/Takeda RNAi collaboration selected as “Deal of the Year”

Last May's agreement between Alnylam and Takeda on a non-exclusive RNA interference platform collaboration focused on oncology and metabolic disease wins in In Vivo Blog's first annual "Deals of the Year" competition. Out of 13 deal candidates, the Alnylam/Takeda tie-up led the voting from start to finish, garnering 35 percent of the votes. The collaboration brought Alnylam $150 million upfront, allowing it to finish the year with about $500 million in cash without restricting its own business prospects or diluting its stock, while also making Takeda Japan's only major player in the RNAi space (1"The Pink Sheet" DAILY, May 27, 2008). In an acceptance speech posted at In Vivo Blog, Alnylam thanked many, including "small molecules and antibodies for giving us undruggable targets" (2In Vivo Blog, Jan. 7, 2009)

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel